Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder

Expert Rev Clin Pharmacol. 2011 May;4(3):311-28. doi: 10.1586/ecp.11.11.

Abstract

The methylphenidate transdermal system (MTS) provides a novel method of delivery for methylphenidate, a well-studied and effective medication for attention-deficit/hyperactivity disorder. The MTS achieves two major goals. First, the delivery system allows for administration throughout the day with a single patch, thus improving adherence. Second, it is the first approved attention-deficit/hyperactivity disorder medication that is not administered orally, thus bypassing gastrointestinal absorption and first-pass metabolism through the enteric circulation. In this article, we review the current data on MTS, including preclinical, clinical and post-marketing studies, and compare efficacy and tolerability to currently available treatments.

Publication types

  • Review

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / metabolism*
  • Central Nervous System Stimulants / administration & dosage
  • Central Nervous System Stimulants / metabolism
  • Clinical Trials as Topic / methods
  • Humans
  • Methylphenidate / administration & dosage*
  • Methylphenidate / metabolism*

Substances

  • Central Nervous System Stimulants
  • Methylphenidate